LAS VEGAS — Skinvisible Inc. has entered into an agreement with specialty pharmacy firm Women’s Choice Pharmaceuticals to develop a prescription formulation using Skinvisible’s patented Invisicare polymer delivery system for topical dermatology products.
Skinvisible said Tuesday that under the pact it received a fee for the development of the product and upon the successful completion the companies will enter into a license agreement that includes a license fee paid in milestones plus ongoing royalties based on product sales.
Development is expected to be completed in the second quarter in anticipation of a third-quarter launch, according to Skinvisible, which makes the Safe4Hours First Aid Antiseptic Skin Protectant.
"We feel that Women’s Choice will be an important licensee for us as we explore other product development opportunities with them that fit with their strategy and expertise in women’s health as well as dermatology. We are especially pleased to be working with the principals as they have a proven track record in the prescription market," Terry Howlett, Skinvisible president and chief executive officer, said in a statement. "This also demonstrates that Skinvisible can help companies accelerate time to market with a patent-protected product that does not come with the high risk and cost associated with bringing new products to the market."
Women’s Choice Pharmaceuticals, based in Gilbert, Ariz., provides technology-based prescription products for the women’s health market.